MS Speaks

Multiple Sclerosis => TREATMENTS => Topic started by: agate on March 02, 2018, 11:46:14 am

Title: Zinbryta (daclizumab) pulled from market due to safety concerns
Post by: agate on March 02, 2018, 11:46:14 am

Zinbryta is being taken off the market, according to MedPage Today (March 2, 2018):


https://www.medpagetoday.com/neurology/multiplesclerosis/71501?xid=NL_breakingnews_2018-03-02&eun=g378374d0r

Title: (Lancet editorial) End of the road for daclizumab in MS
Post by: agate on March 16, 2018, 12:36:35 pm

An editorial in The Lancet (March 17, 2018) sums up the situation with Zinbryta (daclizumab), which has been taken off the market due to safety concerns:


http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30565-8/fulltext?{$trackingTag}

Title: FDA announcement about Zinbryta
Post by: agate on March 20, 2018, 04:28:01 pm

The FDA notification about Zinbryta, which will be available until April 30:


https://www.fda.gov/Drugs/DrugSafety/ucm600999.htm

Title: European EMA confirms severe risks associated w/MS drug Zinbryta
Post by: agate on May 23, 2018, 02:27:15 pm

More on this in Multiple Sclerosis News Today, May 23, 2018--"European EMA Confirms Severe Risks Associated with MS Drug Zinbryta":


https://multiplesclerosisnewstoday.com/2018/05/23/ema-confirms-serious-risks-ms-medicine-zinbryta/?utm_source=Multiple+Sclerosis&utm_campaign=4334878b10-RSS_US_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-4334878b10-71286581

Title: (Abst.) DRESS syndrome and daclizumab failure--were dangerous signs missed in clinical trials?
Post by: agate on July 18, 2018, 11:19:19 am

More on the failure of Zinbryta--from PubMed, July 18, 2018--DRESS syndrome and daclizumab failure--Were potentially dangerous signs missed in clinical trials?":


https://www.ncbi.nlm.nih.gov/pubmed/30013311




DRESS syndrome = drug reaction with eosinophilia and systemic symptoms


This case history (see link below) goes into more detail about DRESS syndrome--appearing in Neurology (September 1, 2018) under the title "Drug reaction with eosinophilia after daclizumab therapy in MS":


http://nn.neurology.org/content/5/5/e479

Title: (Abst.) Case of immune-mediated encephalitis related to daclizumab therapy
Post by: agate on August 04, 2018, 07:00:52 am

From PubMed (August 4, 2018). The same issue of Multiple Sclerosis Journal, which is where the article appears, includes an article entitled "Immune-mediated encephalitis with daclizumab: The final nail."  The article below is entitled "A case of immune-mediated encephalitis related to daclizumab therapy."

https://www.ncbi.nlm.nih.gov/pubmed/30073905

Title: (Abst.) Severe meningo-encephalitis after daclizumab therapy for MS
Post by: agate on January 21, 2019, 09:48:42 pm

The study concerns 7 patients, 2 of whom died. From Multiple Sclerosis Journal (January 19, 2019)--"Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis."

https://journals.sagepub.com/doi/abs/10.1177/1352458518819098

Title: Daclizumab-induced encephalitis in MS
Post by: agate on September 25, 2019, 08:39:04 pm

Editorial in Multiple Sclerosis Journal (September 24, 2019)--"Daclizumab-induced encephalitis in multiple sclerosis":


https://journals.sagepub.com/doi/full/10.1177/1352458519845079